


- artLCMV-PAP-NP/PSA-GP (LCMV based)
- artPICV-PAP-NP/PSA-GP (PICV based)

**FIG. 1A**

- artLCMV-PSMA2-NP/PSMA1-GP
(LCMV based)




FIG. 1B

- artPICV-PSMA1-NP/PSMA2-GP
(PICV based)




FIG. 1C




FIG. 2A





FIG. 2B



PMVS(05)
cl32/05/05

FIG. 3A





FIG. 3B






FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 7E




FIG. 8A




FIG. 8B





FIG. 9A





FIG. 9B

**FIG. 10A**




FIG. 10B




FIG. 10C






FIG. 10D



Alt.=alternating, Approx=approximately, art=artificial, CRPC=castration resistant prostate cancer, GP=glycoprotein, IV=intravenous(y), LCMW=lymphocytic choriomeningitis virus, NP=nucleoprotein, PAP=prostatic acid phosphatase, PICIY=Pichinde virus, PSA=Prostate specific antigen, PSMA=Prostate specific antigen, RP2D=recommended Phase II dose, Seq.=sequential.

NOTE: Further optional dosing alterations to bi-weekly or weekly dosing may be considered following review of dose escalation data by the Investigators and Sponsor Medical Monitor (or designee).

FIG. 11



Abbreviations: DL 1/2/3=dose level 1/2/3; mCRPC= Metastatic Castration Resistant Prostate Cancer, Ph2=Phase 2; RP2D=recommended Phase 2 dose

FIG. 12